IL6 and breast cancer: The results showed that adding exogenous IL-6 to serum obtained from BC patients in T2-T4 stage significantly decreased the accumulation of MDSCs, while adding IL-6 neutralizing antibody (5E1) to serum of BC patients in Ta-T1 stage increased the number of MDSCs (Figure 5).